I have completed my stool tests and blood tests, and my whole abdomen sonography is scheduled shortly. My gastroenterologist prescribed: - Rifax 200 (Rifaximin) - Velgut - Actapro OD 300 I intentionally delayed starting the medications because I was concerned they might influence the investigation results, especially stool tests and inflammatory markers. From an evidence-based perspective: - Is it preferable to start these medications only after the abdomen sonography is also completed? - Or is it acceptable to start them now after blood/stool collection? Please explain whether these medications can meaningfully affect: 1. Stool routine 2. Fecal calprotectin 3. Blood tests (CRP, CBC, etc.) 4. Whole abdomen ultrasound findings I want the most reliable baseline diagnostic evaluation possible.
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
rifaximin gut microbiota stool inflammatory markers
Searching the Web
Actapro OD 300 tablet composition active ingredient gastroenterology
Finding Sources
Finding Sources
Searching the Web
Velgut tablet composition rebamipide India gastroenterology
Finding Sources
Reading File
Reading File
Finding Sources
Searching PubMed
rifaximin calprotectin CRP effect treatment
I now have enough robust information to compose a comprehensive, evidence-based answer. Here is the full analysis:
Your Three Medications — Composition First
| Brand | Active Ingredient | Drug Class |
|---|---|---|
| Rifax 200 | Rifaximin 200 mg | Minimally-absorbed oral antibiotic (rifamycin derivative) |
| Velgut | Rebamipide 100 mg | Gastric cytoprotectant / mucosal protective agent |
| Actapro OD 300 | Acotiamide 300 mg | Prokinetic agent (acetylcholinesterase inhibitor) |
Core Answer: When to Start?
You made a clinically sound decision to wait until stool and blood tests are done. Since those are now completed, starting medications before the ultrasound is entirely safe. The ultrasound will not be meaningfully affected by any of these three drugs. You can — and should — start now.
Detailed Analysis: Do These Drugs Affect Your Tests?
1. Stool Routine (microscopy, occult blood, culture, ova & parasites)
Rifaximin is the only drug here with potential relevance. As a non-absorbed antibiotic achieving fecal concentrations as high as ~8,000 mcg/g (Katzung's Basic and Clinical Pharmacology, 16th Ed.), it acts directly in the gut lumen and can alter the fecal bacterial flora. Starting rifaximin before a stool culture could:
- Suppress pathogenic bacteria you're trying to detect
- Alter commensal flora patterns used to interpret dysbiosis
- Potentially suppress parasites or give false-negative bacterial overgrowth results
Verdict: Correct to hold until stool is collected.
Rebamipide and acotiamide have no antimicrobial activity and would not affect stool microscopy, culture, or occult blood results.
2. Fecal Calprotectin
This is the most important one to reason carefully about.
Fecal calprotectin (FC) is a neutrophil-derived protein released during intestinal mucosal inflammation. It is used to:
- Distinguish IBD from IBS (high sensitivity/specificity)
- Gauge mucosal disease activity in IBD
- Predict relapse
Rifaximin is well documented to have only modest, transient effects on fecal microbiota composition — Yamada's (7th ed.) states it causes "decreases in Peptostreptococcaceae, Verrucomicrobiaceae, and Enterobacteriaceae" but acts more by modulating microbial function than composition. It does not directly suppress neutrophil recruitment or mucosal inflammation. In IBD, even patients in clinical remission on various treatments often maintain elevated FC.
However, in theory, if your GI inflammation is being driven entirely by bacterial overgrowth (e.g., SIBO), treating it with rifaximin could begin to reduce mucosal inflammation and lower FC before your baseline is established. This effect would take days to weeks and is modest — but it is a legitimate reason the FC should be measured before starting the antibiotic.
Verdict: Already protected — you collected stool before starting. Good decision.
Rebamipide increases mucosal prostaglandin production and mucus synthesis. It does not suppress inflammatory cell infiltration acutely enough to falsely normalize FC before a collection. Acotiamide has no mucosal anti-inflammatory mechanism at all.
3. Blood Tests — CRP, CBC, ESR
CRP: Rifaximin's clinical mechanism in IBS and hepatic encephalopathy involves modulating gut microbial function rather than dramatically reducing systemic inflammation. CRP changes from rifaximin take at minimum several days to become measurable, and even then the effect is modest in functional GI conditions. For a single pre-treatment CRP, starting rifaximin now poses negligible risk to interpreting a value already drawn.
Acotiamide (prokinetic — inhibits acetylcholinesterase and muscarinic M1/M2 receptors in the stomach): No effect on CRP, WBC, platelets, ESR, or any standard hematological/inflammatory marker.
Rebamipide (cytoprotective): Stimulates prostaglandin E2 and mucosal mucus. No known effect on systemic inflammatory markers at standard doses.
Verdict: Blood tests already collected → zero concern. These medications would not have altered CRP or CBC even if started earlier.
4. Whole Abdomen Ultrasound
This is where you can comfortably start treatment now. None of these three drugs meaningfully alter ultrasound findings:
| Drug | Any US Impact? |
|---|---|
| Rifaximin | No. Acts intraluminally; does not change organ echogenicity, gallbladder wall, liver parenchyma, or bowel wall thickness in the short term |
| Rebamipide | No. Mucosal cytoprotection — no structural US changes |
| Acotiamide | Accelerates gastric emptying. Theoretically, if US included a gastric emptying assessment, this could be relevant — but whole abdomen USS for GI workup does not assess gastric emptying kinetics. No relevant impact. |
A few days of these medications before the ultrasound would not change any sonographic finding that your gastroenterologist is evaluating (bowel wall thickness, free fluid, organomegaly, gallstones, lymph nodes, mesenteric fat, etc.).
Summary Recommendation
| Test | Start Before? | Reasoning |
|---|---|---|
| Stool routine + culture | ✅ Already done — correct to wait | Rifaximin would suppress flora |
| Fecal calprotectin | ✅ Already done — correct to wait | Rifaximin could modestly reduce mucosal inflammation over days |
| CRP / CBC / ESR | ✅ Already done — no concern either way | None of these drugs acutely alter blood markers |
| Whole abdomen sonography | ✅ Start medications now | No drug in this regimen affects sonographic findings |
You can safely begin all three medications today. Your stool and blood baseline has been protected. The ultrasound will not be influenced by a few days of rifaximin, rebamipide, or acotiamide.
Note: This analysis is for informational purposes. Your gastroenterologist who has access to your clinical history and investigation results is best positioned to finalize the timing. Given that your stool tests are already complete, starting as prescribed is medically appropriate.
This is a shared conversation. Sign in to Orris to start your own chat.